🔴 Relay Therapeutics is trading 4% down with no confirmed company-specific catalyst

Relay Therapeutics is trading 4.00% down at $17.99, with no clear company-specific catalyst identified.

• No clear October 7 company announcement explaining the decline surfaced in the search.
• A Form 144 filed October 6 disclosed an officer’s proposed share sale; available reporting does not establish it as the cause.
• Broader biotech and risk sentiment also faced pressure: supplied context shows XBI down 2.50%, while elevated Treasury yields, oil and geopolitical concerns weighed on markets. This is sector-wide context, not a confirmed company-specific catalyst.